US Patent Issued to The University of North Carolina at Chapel Hill on April 21 for "AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB" (North Carolina Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,605,465, issued on April 21, was assigned to The University of North Carolina at Chapel Hill (Chapel Hill, N.C.).

"AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB" was invented by Haiyan Fu (Durham, N.C.) and Tierra Bobo (Mebane, N.C.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Recombinant nucleic acid comprising nucleotides encoding Alpha-N-acetylglucosaminidase (NAGLU). Vectors comprising the recombinant nucleic acid for delivery to a subject. In an aspect the NAGLU sequences optimized for expression in human cells. Methods of using the vector to increase secretion of NAGLU from a cell and for treatment and prevention of mucopolysacc...